| Market Cap | 351.02M | P/E | - | EPS this Y | 0.40% | Ern Qtrly Grth | - |
| Income | -68.52M | Forward P/E | -2.53 | EPS next Y | -43.20% | 50D Avg Chg | -23.00% |
| Sales | 68.68M | PEG | - | EPS past 5Y | - | 200D Avg Chg | -31.00% |
| Dividend | N/A | Price/Book | 1.40 | EPS next 5Y | - | 52W High Chg | -55.00% |
| Recommedations | 2.00 | Quick Ratio | 7.08 | Shares Outstanding | 42.45M | 52W Low Chg | 1.00% |
| Insider Own | 0.96% | ROA | -22.30% | Shares Float | 20.11M | Beta | 0.70 |
| Inst Own | 87.35% | ROE | -30.52% | Shares Shorted/Prior | 721.30K/747.48K | Price | 8.34 |
| Gross Margin | -87.28% | Profit Margin | -99.76% | Avg. Volume | 100,662 | Target Price | 13.71 |
| Oper. Margin | -3,478.01% | Earnings Date | Aug 6 | Volume | 78,943 | Change | -7.13% |
Repare Therapeutics Inc., a clinical-stage precision oncology company, engages in the discovery and development of therapeutics by using its synthetic lethality approach in Canada and the United States. It uses its SNIPRx, a proprietary, genome-wide, and CRISPR-enabled platform, to discover, validate, and build a pipeline of SL-based therapeutics that focuses on genomic instability, including DNA damage repair. The company's lead product candidate is Camonsertib (RP-3500), an oral small molecule inhibitor under Phase ½ development for the treatment of solid tumors with specific DNA damage repair-related genomic alterations. It is also developing Lunresertib (RP-6306), a PKMYT1 Inhibitor, which is under Phase I/Ib clinical trial for tumors with genetic alterations characterized by CCNE1 amplification; RP-1664, an oral PLK4 inhibitor, under Phase 1 clinical trial designed to harness the synthetic lethal relationship with TRIM37 amplification or overexpression in solid tumors; and RP-3467, a polymerase theta adenosinetriphosphatase (ATPase) inhibitor, a SL target associated with BRCA mutations and other genomic alterations. The company has license and collaboration agreement with Hoffmann-La Roche Inc. and F. Hoffmann-La Roche Ltd; Bristol-Myers Squibb Company; New York University; with Foundation Medicine, Inc. for the provision of prospective genomic profiling of lunresertib alone or in combinations in genomically-defined patient populations; and Ono Pharmaceutical Co., as well as a clinical study and collaboration agreement with Debiopharm to explore the synthetic lethal combination of PKMYT1 and WEE1 inhibition in cancer. Repare Therapeutics Inc. was incorporated in 2016 and is headquartered in Montréal, Canada.
| HC Wainwright & Co. | Buy | Sep 4, 24 |
| HC Wainwright & Co. | Buy | Jun 5, 24 |
| HC Wainwright & Co. | Buy | May 30, 24 |
| HC Wainwright & Co. | Buy | Mar 8, 24 |
| HC Wainwright & Co. | Buy | Feb 21, 24 |
| HC Wainwright & Co. | Buy | Feb 14, 24 |
| HC Wainwright & Co. | Buy | Nov 20, 23 |
| Piper Sandler | Overweight | Oct 16, 23 |
| Stifel | Buy | Sep 25, 23 |
| Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| BVF PARTNERS L P/IL | 10% Owner 10% Owner | Nov 02 | Buy | 3.6 | 783,709 | 2,821,352 | 485,083 | 11/03/23 |
| Zinda Michael | EVP, Chief Scientifi.. EVP, Chief Scientific Officer | Jun 06 | Sell | 12.04 | 1,200 | 14,448 | 69,391 | 06/07/23 |
| Koehler Maria | EVP, Chief Medical O.. EVP, Chief Medical Officer | Dec 20 | Option | 2.24 | 48,507 | 108,656 | 149,513 | 12/20/22 |
| BVF PARTNERS L P/IL | 10% Owner 10% Owner | Jun 13 | Buy | 12.73 | 149,161 | 1,898,820 | 412,604 | 06/15/22 |
| BVF PARTNERS L P/IL | 10% Owner 10% Owner | Jun 02 | Buy | 12.39 | 1,836,958 | 22,759,910 | 406,436 | 06/06/22 |
| BVF PARTNERS L P/IL | 10% Owner 10% Owner | May 18 | Buy | 8.5 | 420,000 | 3,570,000 | 313,357 | 05/20/22 |
| BVF PARTNERS L P/IL | 10% Owner 10% Owner | Jan 19 | Buy | 14.1 | 997,961 | 14,071,250 | 307,627 | 01/21/22 |
| Zinda Michael | EVP, Chief Science O.. EVP, Chief Science Officer | Nov 15 | Sell | 27.54 | 20,000 | 550,800 | 533 | 11/17/21 |
| Bonita David P | Director Director | Sep 08 | Sell | 33.97 | 8,084 | 274,613 | 96,190 | 09/08/21 |
| ORBIMED ADVISORS LLC | Director Director | Sep 08 | Sell | 33.97 | 8,084 | 274,613 | 96,190 | 09/08/21 |